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Tissue grafts are the gold standard for replacing large volume tissue defects. Yet, they present 
several risks, including infection, low functional outcomes, and reduced graft integrity. Tissue 
engineering (TE) combines cells and biomaterial scaffolds to foster tissue growth and remodeling. 
Bone marrow stromal cells (BMSCs) have been shown to respond to the stiffness of their 
microenvironment, resulting in differentiation into different lineages. 3D porous chitosan-alginate 
(CA) scaffolds have been previously demonstrated for bone TE with osteoblasts and BMSCs; 
however, only a single scaffold composition (4 wt%) was studied. Three CA scaffold compositions 
(2, 4, 6 wt% CA) were produced. Scanning electron microscopy images were obtained to 
determine average pore sizes for 2, 4, and 6 wt% CA scaffolds, which were 233, 208, and 146 µm. 
Compression testing was performed on CA scaffolds in dry and wet conditions, where higher 
concentrations yielded higher stiffnesses ranging from 0.22 to 5.34 kPa and 21.1 to 47.3 Pa, 
respectively. Fourier transform infrared spectroscopy performed on the CA scaffolds confirmed 
polyelectrolyte complex formation for all compositions. Human BMSCs from three donors were 
seeded on CA scaffolds, cultured in growth media for 14 days, then cultured in adipogenic or 
osteogenic differentiation media for 28 days to promote differentiation. Our hypothesis was that 
scaffold stiffness would influence BMSC differentiation, with softer scaffolds promoting 
adipogenesis and stiffer scaffolds promoting osteogenesis. BMSCs formed multicellular spheroids 
in all CA scaffold concentrations, while the 2 wt% CA scaffolds had smaller spheroids compared 
to the 4 wt% and 6 wt% CA scaffolds. Osteogenic and adipogenic differentiation were evaluated 
with Alizarin Red and Oil Red O staining, respectively. While positive staining was observed in 
all scaffold compositions, more robust differentiation was expected, thereby disproving our 
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hypothesis. The polysaccharide composition of the CA scaffolds likely contributed to the spheroid 
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CHAPTER 1: INTRODUCTION 
Large volume tissue defects caused by trauma, congenital defects, or disease present a great 
challenge for reconstructive surgeons. While traditional tissue grafts such as allografts and 
autografts present viable alternatives, there are also many drawbacks associated with them. These 
types of treatments are an insufficient solution due to their high risk of infection, lack of 
availability, and poor functional outcome. Tissue engineering is an interdisciplinary field that aims 
to develop solutions that can help enhance, replace, or restore damaged tissues. The main approach 
of tissue engineering is to combine cells and biomaterials to develop functional tissues that can be 
implanted at the site of injury in a patient. 
A common approach is to use BMSCs (bone marrow stromal cells) and biomaterial 
scaffolds resulting in increased osteogenesis in model systems in vitro. It has also been shown that 
BMSCs are responsive to the stiffness of their microenvironment. Therefore, it is of great 
importance to better understand cell-material interactions, specifically concerning BMSC 
microenvironment stiffness and lineage differentiation, in order to move the tissue engineering 
field forward. Chitosan Alginate (CA) scaffolds have been previously demonstrated for bone tissue 
engineering applications with osteoblasts and BMSCs [1, 2]. Yet, only a single CA composition 
(4 wt%) has been studied. This thesis examines the effects of CA scaffold stiffness variations (2, 
4, 6 wt%) on the differentiation of three BMSC donors. Understanding BMSC donor variation is 
an important step towards the ultimate goal of TE, which is to develop biomaterials that have 
specific regenerative effects in a large patient population. 
The first chapter includes a literature review that covers essential topics in the field starting 
with the clinical need, tissue engineering, and biomaterials for tissue engineering, including a 
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section on CA scaffolds. The second chapter is the methodology section which includes a 
description of the CA scaffolds synthesis, materials characterization, cell culture, and cellular 
analysis. The third chapter presents the results from the scaffold characterization and cell culture 
studies, including SEM, mechanical testing, FTIR, cell proliferation assays, cell proliferation 
imaging, and differentiation staining. The fourth chapter covers the discussion and conclusions 
upon which the relationship between CA scaffold stiffness and BMSC differentiation is elucidated. 










  CHAPTER 2: LITERATURE REVIEW 
Clinical Need 
Surgical reconstruction of tissue defects is one of today’s biggest healthcare challenges and 
expenditures. When tissue defects are large enough that the body can’t heal them on its own, tissue 
grafts are surgically implanted into the defect site. These types of injuries are called “critical-sized 
defects” and occur when the non-regenerative threshold of bone tissue has been reached [3]. The 
2017 U.S. average estimated cost of all organ transplants was $2.26 billion for people under age 
65 and $625 million for people over age 65 [2]. Autografts, which are tissue or organ transplants 
from one part of a person to another location in the same person, are often considered the “gold 
standard” for replacing diseased or damaged tissues. Yet, they present several risks including 
donor site morbidity, infection, low functional and cosmetic outcome, and reduced graft integrity 
[5]. Allografts, which are tissue or organ transplants from another person, remove the complication 
of donor site morbidity. However, they can occasionally trigger an immunogenic response which 
requires recipients to be placed on immunosuppressant drugs to prevent rejection [6]. Additionally, 
allografts are typically frozen, irradiated and/or lyophilized to reduce the likelihood of disease 
transmission, which can compromise their mechanical integrity and reduce bioactivity. Therefore, 
while allografts are a viable tissue replacement alternative, they still carry many of the risks 
associated with autografts. Additionally, both autografts and allografts have a limited supply that 
can fail to meet the needs of larger defects.  
In order to overcome the issues associated with tissue and organ grafts, scientists and 
engineers are developing innovative biomaterials to repair or replace damaged tissues. The 
biomaterials field is highly multidisciplinary and it studies materials with a special focus on their 
interaction with the biological environment for primarily medical purposes, such as therapeutic or 
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diagnostic applications [7]. The biology of host-material interactions strongly determines the 
biocompatibility of a material. Biocompatibility is defined as the ability of a biomaterial to 
generate an appropriate host response within its application, which includes resistance to blood 
clotting, resistance to bacterial colonization, and regular healing [3, 4]. Besides their enhanced 
biocompatibility and increased supply, biomaterials can also be designed to fit the specific tissue 
graft needs of a patient. Therefore, as the rates of chronic disease and the aging population continue 
to increase, the human impact and commercial market size for the biomaterials field are projected 
to expand.   
 Tissue Engineering 
 Tissue engineering is a branch of biomedical engineering that focuses on the design and 
fabrication of biomaterials to repair or replace damaged tissues and organs by developing 
substitutes or reconstructing them as an alternative to conventional tissue grafts. The tissue 
engineering field is highly interdisciplinary as it requires the collaboration of materials scientists, 
cell biologists, chemists, and engineers. The main strategy is to combine cells and biomaterials 
that are used to grow or foster the remodeling of tissues and organs [9]. As can be observed in 
Figure 1, cells can be harvested from a patient (1), expanded through cell culture in vitro (2), 
seeded into a biomaterial (3), cultured for proliferation (4), and finally implanted at the site of 
injury in a patient (5).  
Three-dimensional (3D) biomaterials recreate the extracellular matrix (ECM) environment 
and provide mechanical support for newly formed tissues [10]. 3D biomaterials can take different 
forms, such as nanofiber scaffolds, hydrogels, and 3D porous sponges, among others. Scaffolds 
are porous biomaterials that (i) promote cell-material interactions and ECM deposition, (ii) allow 
sufficient gas, nutrient, and growth factor transport for cell survival, proliferation, and 
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differentiation, (iii) degrade at a controlled rate that matches that of native tissue, (iv) cause 
minimal inflammation or in vivo cytotoxicity [11]. The 3D scaffold also allows for cell migration 
and proliferation followed by the secretion of native ECM, which can lead to a complete and 
natural long term tissue replacement [12]. 
 
 
Figure 1. Diagram of the classical tissue engineering model. Cells are harvested from a patient (1), 
expanded in vitro (2), cultured within a biomaterial scaffold (3-4), and  implanted at the site of injury (5).  
 
A common approach in tissue engineering involves harvesting primary stem cells from a 
patient and culturing them in vitro in a 3D scaffold (Figure 2a). Cultures within scaffolds can be 
grown in a static (incubator) or a dynamic (bioreactor) environment. After cells proliferate and 
differentiate into specific tissues, the tissue engineered constructs are implanted at the site of injury 
to help regenerate damaged tissues. A second approach involves implanting or injecting the 3D 
scaffolds in vivo and allowing tissue formation and ingrowth to occur in situ (Figure 2b). In this 
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case, scaffolds are implanted without cells and the patient is used as an incubator to grow the tissue 
or organ, where cells in the surrounding tissue spontaneously populate the scaffold.  
Figure 2. Two main approaches to tissue engineering: (A) Transplantation of in vitro grown tissues and 
(B) Promotion of tissue regeneration in situ [8]. 
 
Biomaterials can be biocompatible, bioactive, and biodegradable depending on their 
specific application. For example, a hip implant ideally would not be biodegradable in order to 
provide long term mechanical support, while a skin graft would ideally degrade at a rate matching 
the regenerating tissue. Biocompatibility prevents an adverse immune response from the patient, 
bioactivity stimulates cell regeneration, and biodegradation accommodates neo-tissue formation. 
The scaffold stiffness is typically chosen to match that of the target native tissue and is sufficient 
to withstand long-term culture and implantation. The main challenges preventing the clinical 
translation of these products include achieving sufficient biological function from cellularized 
constructs, optimal host biocompatibility, and cost reduction [13]. It is expected that advances in 
stem cells, biomaterials, biofabrication, and immunomodulation will speed the clinical application 
of tissue engineering products by tackling these challenges.  
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Bone Marrow Stromal Cells in Tissue Engineering 
  Mesenchymal stem cells (MSCs) are multipotent progenitor cells that have the potential to 
differentiate into different end-stage mesenchymal cell types, including bone, cartilage, muscle, 
bone marrow stroma, tendon/ligament, fat, dermis, and other connective tissues, as can be 
observed in Figure 3 [14]. MSCs reside in a variety of tissues and have the ability to regenerate 
cell types of the previously mentioned tissues. One type of MSCs, bone marrow stromal cells 
(BMSCs) are non-hematopoietic adherent cells, a subset of which are skeletal stem cells (SSCs) 
that can form cartilage, bone, hematopoiesis-supportive stroma, and marrow adipocytes [15]. 
Besides being undifferentiated, BMSCs have significant self-renewal capacities. Therefore, these 
cells are very useful in the practices of bone tissue engineering and regenerative medicine.   
 





  One of the most common ways to obtain BMSCs is through bone marrow aspirate from 
the iliac crest which is considered to be one of its most accessible and enriched sources. 
Alternatively, adipose derived stromal cells (ADSCs) can be derived from adipose tissue and 
resemble BMSCs in morphology, phenotype, and differentiation capacity [17]. Both BMSCs and 
ADCSs have finite life spans despite advancements in long term culture expansion. This occurs 
since they undergo telomere shortening after each division cycle, which results in gradual 
senescence [18]. BMSCs were found to decrease in adipogenic potential after 7 passages, with 1 
in 2035 cells being capable of differentiating into an adipocyte at passage 7 [19]. BMSCs were 
found to MSCs play a significant role in development, as well as adult tissue repair.  
BMSCs for Bone Tissue Engineering 
  The osteogenic induction of BMSCs is a highly programmed process that has been 
extensively studied in vitro and stimulates osteoblast formation. Osteoblasts are relevant cells for 
bone tissue engineering since they are in charge of secreting unmineralized, collagen-rich osteoids, 
upon which bone mineralization occurs [20]. The synthetic glucocorticoid dexamethasone (DEX) 
stimulates MSC proliferation and osteogenic differentiation [21]. Organic phosphates like -
glycerolphosphate (BGP) enhance osteogenesis by supporting the mineralization and modulation 
of osteoblast activity [22]. Additionally, free phosphate groups induce the mRNA and protein 
expression of osteopontin, as well as influence the production and nuclear export of the osteogenic 
regulatory gene Cbfa1 (core binding factor alpha 1) [28, 29]. Supplements such as L-ascorbic acid 
(LAA) are also commonly used for osteogenic induction.  
  The osteogenic differentiation of BMSCs can be confirmed by different bone matrix 
molecules, mineral crystals, and nodules. An early indicator of BMSC osteogenic differentiation 
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is the upregulation of alkaline phosphatase activity. Additionally, the presence of mineralized 
BMSC matrix can be verified with von Kossa or Alizarin Red stains [25]. Osteocalcin, osteopontin, 
and osteonectin are non-collagenous proteins found in the bone matrix and late osteogenic 
differentiation markers that can be measured using RT-PCR or proteomically using ELISA [25]. 
Many natural and synthetic biomaterials have shown promise as carriers for MSC delivery in 
orthopedic therapeutic applications such as polysaccharides (chitosan, alginate, or hyaluronic acid) 
PCL, PLA, and PLGA [26]. Advances in the biomaterials field have led to a transition from inert, 
non-porous materials to highly porous, osteoconductive, cell-matrix composite materials. 
BMSCs for Adipose Tissue Engineering  
  A large proportion of surgical procedures performed each year are to repair soft tissue 
defects resulting from a loss of adipose tissue. Therefore, the field of adipose tissue engineering is 
necessary in these cases. Adipogenic induction of BMSCs is a complex process that is controlled 
by steroid hormones, transcription factors, and secreted cytokines/adipokines [27]. BMSC 
adipogenic induction yields adipocytes which are characterized by lipid droplet formation [28]. 
Bone marrow adipocytes are thought to differentiate from BMSCs in vitro and in vivo. In vitro 
induction of BMSCs requires specific media supplementations. Adipogenic medium for 
differentiation usually includes dexamethasone (DEX), 3-isobutyl-1-methylxanthine (IBMX), and 
indomethacin (IM) [14]. Indomethacin is an anti-inflammatory drug that binds to and activates the 
transcription factor peroxisome receptor gamma (PPAR-).  
  One of the most important factors in BMSC adipogenic differentiation in PPAR-2, which 
can be detected through RT-PCR [25]. Additionally, Oil Red O is a stain that binds to lipid 
vacuoles synthesized intracellularly by BMSC-derived adipogenic cells. Common adipogenic 
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gene products, such as lipoprotein lipase (LPL) and polyclonal antibody anti-P2, can be amplified 
and detected through RT-PCR [29]. Adipose tissue accumulates lipid vacuoles intracellularly and 
the extracellular matrix consists of interstitial fibrous tissue, nerve supplies, and vascular 
lymphatic network [25]. Both synthetic polymers (i.e. PLA, PLGA, PEG) and natural polymers 
(i.e. collagen, fibrin, gelatin) have been explored for adipose tissue engineering applications with 
considerable differences in material biocompatibility, mechanical and chemical properties. 
Collagen is one of the most prevalent natural polymers used for adipose tissue engineering due to 
its natural prevalence in native adipose ECM, which allows it to promote favorable adipose 
outcomes [30]. Other natural polymers used in adipose tissue engineering include adipose-derived 
ECM, decellularized human placenta, hyaluronan, and matrigel. 
Mechanotransduction 
 Stem cell maintenance and differentiation are influenced by different aspects of their 
microenvironment, including matrix structure, chemistry, and stiffness. ECM proteins have unique 
distributions and assembly patterns in different tissues which contribute to developmental 
processes, since the initiation of matrix expression precedes the generation of pluripotent 
embryonic stem cells (ESCs) and the onset of cell movement [31]. Additionally, fibronectin 
regulates cell migration during gastrulation, which occurs as stem cell fate is being established 
[31]. While ESCs have a temporally changing matrix that may be linked to differentiation, MSCs 
are known to actively migrate to tissues with different matrix compositions [29]. Therefore, the 
influence of matrix variations towards MSC differentiation is worth examining. 
Cells can actively sense their environment and respond to matrix physical and chemical 
cues through focal adhesions. Focal adhesions are large protein assembly complexes that 
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physically couple the ECM to the intracellular actin cytoskeleton [32]. Integrins, the major 
adhesion receptors, are heterodimers comprised of  and  subunits that have high binding affinity 
for specific ECM proteins and assemble to link the extracellular and intracellular environments 
[33]. Additionally, integrins allow for bidirectional outside-in and inside-out force transfer and 
signal transmission [34]. As cells first secrete matrix proteins in vivo, integrins rearrange these 
molecules [35]. Adapter proteins, such as talin and viculin, connect integrins to the actin 
cytoskeleton, which is in turn connected to the nucleus as can be observed in Figure 4 [32]. 
Therefore, integrins are vital surface transmembrane receptors that can also mediate focal adhesion 
assembly, cytoskeletal organization, and a cascade of downstream signal transduction events that 
ultimately regulate gene expression and cell behavior [34].  
 
Figure 4. Mechanical forces applied to cells are transmitted across integrin receptors into cytoplasmic 
domains. Forces concentrated in the focal adhesions stimulate clustering of dimeric (,) integrin 





Cells can sense their microenvironment stiffness by pulling against the ECM and assessing 
its resistance to deformation through focal adhesions. The resistance that a cell feels as it pulls on 
the ECM is the matrix elastic constant or stiffness, which varies widely across different tissues 
types. For example, the matrix elastic constant in collagenous bone (100 kPa) is a lot higher than 
in muscle (10 kPa) and brain (1 kPa) tissues [36]. Cells also alter matrix mechanics by exerting 
different forces on the ECM, thereby establishing a feedback loop that can influence cell fate and 
function [32]. This dynamic process of cell-ECM mechanical interactions is called 
mechanotransduction. These interactions are mediated by integrin proteins within focal adhesion 
complexes that transmit mechanical forces across the cell surface. Cells exert these cytoskeleton-
generated contractile forces through the same integrin-ECM bonds that help them sense matrix 
stiffness [37]. Focal adhesions are therefore key elements for mechanotransduction, as they bear 
high mechanical loads and even contain signaling molecules that change their activity under 
mechanical stress [38]. Forces concentrated within focal adhesions stimulate clustering of dimeric 
integrin proteins and recruitment of focal adhesion proteins (i.e. talin, vinulin, paxillin) as can be 
observed in Figure 5 [34].  
Biomaterial structure can also strongly influence how a cell senses its microenvironment. 
For example, when a polymer foam material has pore sizes that are much greater than the cell size, 
a relatively flat or slightly curved substrate material is effectively presented to the cell as it adheres 
to a strut. In this case, the basal surface of a cell will attach to the material, which induces a 
response similar to those observed on planar substrates where high cellular forces occur on stiff 
materials [32]. On the other hand, smaller pore sizes allow the cell to attach to the material in all 
dimensions and yield smaller forces than those observed on planar substrates [31]. Yet, it is 
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important to note that cell-material interactions are fast changing, and that the matrix synthesized 
by a cell can become a relevant variable to guide cell fate at later timepoints. Besides the stiffness, 
cells are also exposed to mechanical forces from fluid flow and matrix strain which stimulate 




Figure 5. Cells present a small spreading area on soft matrices, associated with poorly defined 
cytoskeleton, detachment of focal adhesion complexes, and integrin uptake. On substrates with medium 
stiffness, cells develop elongated focal adhesions and well aligned stress fibers. On rigid matrices, cells 
display a large spreading area, prominent stress fibers, and enhanced focal adhesion assembly [34].  
 
Cells can also obtain cues regarding matrix chemistry through the specific subset of 
integrins that interacts with the matrix. Additionally, the presence of certain ECM proteins can 
influence cell adhesion and differentiation [39]. This occurs through ligand conformational 
changes that enhance force transmission to integrins on the surface of the cell [40]. Regional 
differences in receptor-ligand distribution have been shown to control MSC osteogenic 
differentiation [39]. Matrix chemistry can also be altered by using recombinant proteins that 
contain adhesion molecules, such as RGD peptides. Even variation in reactive surface groups, such 
as methyl versus carboxyl, can alter cell adhesion and induce change between self-renewal and 
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differentiation [41]. Matrix adhesion enhancements, through surface coatings and crosslinking can 
also improve cell adhesion to matrices and possibly alter integrin expression as well as cell 
differentiation [42]. Other cell types, besides stem cells, are also responsive to differences in 
adhesive ligand concentrations, such as malignant phenotypes in mammary epithelial cells that are 
induced by high levels of fibronectin [43]. Growth factors can also become sequestered within the 
ECM to be later released by proteolytic degradation or by cell-generated forces [44].  
Biomaterials for Tissue Engineering 
  A variety of factors influence the material selection for a tissue engineering application, 
such as biocompatibility, surface chemistry, molecular weight, microstructure, degradability, 
processability, and mechanical properties [45]. Biomaterials used for tissue repair include metals, 
ceramics, and polymers. Metal based biomaterials are good for load bearing applications due to 
their high mechanical properties and resistance to wear and shock. Ceramic based biomaterials are 
mostly bioinert, have high elastic moduli, and compression resistance. Polymer based scaffolds 
have unique properties such as high surface to volume ratio, high interconnected porosity, 
controlled degradation, and tunable mechanical properties [11]. Additionally, polymers and their 
degradation products usually have lower toxicity and better resemble natural ECM. Therefore, 
polymer biomaterials have been widely used for the fabrication of medical devices and scaffolds 
for tissue engineering. Researchers have attempted to grow a variety of tissues on polymer based 
scaffolds, such as skin [46], bone [47], liver [48], heart grafts [49], pancreas [50], bladder [51], 
corneas [52], and other soft tissues. Polymer based biomaterials can be natural or synthetic and 
degradable or non-degradable according to their intended use. The final properties of the polymer 
scaffold are dependent on its composition, structure, and macromolecular arrangement [11]. 
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Synthetic Polymers   
  Synthetic biomaterials are advantageous for tissue engineering applications due to their 
simple processability into specific shapes and structures, high control of mechanical strength and 
degradation kinetics, lack of immunogenicity, as well as easy post-modification for specific 
applications [53]. Additionally, synthetic polymers are usually cheaper than natural materials and 
can be uniformly fabricated in large quantities with a long shelf time [54]. Generally, synthetic 
polymers have reproducible and predictable mechanical and physical properties, such as elastic 
modulus and degradation kinetics, that ease their scale-up and manufacture [11]. While synthetic 
polymers have great advantages due to the easy tunability of their mechanical properties and 
degradation kinetics, they also present some drawbacks such as poor biocompatibility, release of 
acidic degradation products, and rapid loss of mechanical properties [55]. Unfavorable byproducts 
can obstruct tissue regeneration and even result in inflammation or fibrous encapsulation [55]. 
Additionally, they lack biological cues which can impede cellular adhesion and interaction [56]. 
A way to overcome this challenge is to modify synthetic polymers with bioactive molecules. 
Some of the most commonly used synthetic polymers in tissue engineering include 
polyesters such as polylactic acid (PLA), polyglycolic acid (PGA), and their copolymer polylactic-
co-glycolic acid (PLGA). These polymers have been widely used for tissue engineering due to 
their high biodegradability through the hydrolysis of ester bonds, minimal inflammatory response, 
and highly controlled degradation [57]. PLA has one additional methyl group than PGA in its 
repeating unit which makes it more hydrophobic and reduces its hydrolysis rate. PLA scaffolds 
can take months or years to lose their mechanical integrity both in vitro and in vivo [58]. PGA has 
a relatively hydrophilic nature which causes its rapid degradation in aqueous solutions and in vivo, 
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ultimately compromising its mechanical integrity within two to four weeks [22]. In order to 
achieve intermediate degradation rates, PLGA with different lactic to glycolic acid ratios can be 
synthesized. 
Natural Polymers  
  Natural polymers were the first materials to have been used medically, since ancient 
Egyptians used animal tendons as sutures [59]. Due to their bioactive nature, natural polymers 
have often superior cell-material interactions which enhance their performance within a biological 
system [11]. Additionally, they are biodegradable, biocompatible, and similar to the ECM. Their 
main drawbacks include batch to batch variability, lower control of mechanical properties, and 
limited processability. The two main classes of natural polymers used for tissue engineering 
applications are proteins and polysaccharides.   
  Proteins include silk, collagen, fibrin, gelatin, elastin, and keratin, among others. The main 
motivation for using protein based polymers is that they mimic proteins in the ECM, thereby 
having the ability to direct cell migration, growth and organization during tissue regeneration. 
Collagen has 28 different identified types, but type I is the most common in the human body. 
Collagen is also a major component of the fibrillar extracellular matrix and it provides essential 
signals for cell regulation, anchorage, migration and proliferation [60]. As a result it has been 
studied for artificial skin (collagen IV), bone (collagen I), and cartilage (collagen II), resulting in 
many tissue engineering products [61].  
  Gelatin is a natural polymer derived from collagen that is known for its biodegradability 
and biocompatibility within the physiological environment. More specifically, gelatin is obtained 
by acid and alkaline processing of collagen. Additionally, gelatin is a good carrier of bioactive 
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molecules, such as fibroblast growth factor, and has low immunogenicity [62], [63]. Gelatin has 
been widely used for tissue engineering applications, such as in chitosan-
gelatin/nanohydroxyapatite composite scaffolds for bone tissue engineering [64]. Silk is a protein 
polymer that is spun into fibers by lepidoptera larvae, such as silkworms, spiders, etc. Silk has 
received great attention due to its high strength to weight ratio and slow degradation [65]. Silk 
fibroin, a natural polymer made by silkworms that can be mass produced, is commonly used as a 
textile fiber and for surgical sutures in the medical field [66]. Additionally, silk fibroin has been 
successfully investigated for the tissue engineering of bone, cartilage, and ligaments [67]. 
  Fibrin is a matrix protein made from the fibrinogen precursor, which self-polymerizes in 
presence of the enzyme thrombin that triggers a coagulation cascade is response to vascular injury 
[66]. This coagulation response also helps establish a fibrin based provisional matrix at the injury 
site that provides structural and biochemical support for wound healing. Due to its ability to 
enhance cell migration, fibrin has been explored for tissue engineering applications [68]. As a 
result, fibrin has been used to study bone, cartilage, skin, nerve, and spinal cord regeneration [69].  
  Polysaccharides are macromolecules that consist of monosaccharides linked by o-
glycosidic bonds that form branched and linear structures [54]. Polysaccharides include chitosan, 
alginate, amylose, cellulose, hyaluronic acid, and chondroitin sulfate. Glycosaminoglycans, such 
as hyaluronic acid and chondroitin sulfate, are polysaccharides naturally found in the ECM that 
also have excellent biocompatibility and bioactivity [11].  Using polysaccharides for tissue 
engineering is highly advantageous since they are naturally found in the ECM and contribute to 
cell signaling and growth [70]. Therefore, polysaccharides are easily recognized in the biological 
environment and have both high biocompatibility and bioactivity which makes them promising 
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materials for the tissue engineering field. 
  Chitosan is a cationic polymer derived from chitin found in the shell of crustaceans that 
has shown high biocompatibility, ease of scaffold fabrication, and promise for tissue engineering 
applications in skin, bone, cartilage, and vascular graft regeneration [66]. Chitosan is composed of 
N-acetyl-glucosamine and N-glucosamine units and it is obtained through the alkaline 
deacetylation of chitin, a linear polymer made of N-acetyl-glucosamine. Once the degree of 
deacetylation (DD) of chitin exceeds 50%, the polymer is called chitosan. Chitosan is soluble in 
dilute acidic conditions, such as in acetic acid solutions, under which its amino groups protonate 
[71]. Chitosan can be ionically crosslinked, form polyelectrolyte complexes (PEC), or be 
covalently crosslinked, which allow for pH neutralization and enhanced mechanical properties. 
PECs form once the cationic chitosan is combined with a negatively charged polymer, such as 
alginate, to form an ionic network [72]. Chitosan is a biodegradable material as it can be degraded 
by human enzymes, such as lysozyme. Chitosan has multiple hydroxyl and amino function groups 
that provide sites for chemical modifications. Therefore, many research groups have explored 
attaching biomolecules to chitosan by covalent bonding, ionic bonding, or adsorption.   
  Alginate is brown algae derived anionic polysaccharide that has been used in the form of 
hydrogels, beads, and scaffolds for tissue engineering applications due to its pro-angiogenic and 
regenerative properties [73]. The molecular weight of alginate can range from 50 kDa to 100,000 
kDa. Alginates are composed of (1,4)-linked -D-mannuronic acid (M) and -L-guluronic acid 
(G) units within homopolymer blocks of similar (i.e. MMMM, GGGG) or alternating sections (i.e. 
MGMG) [73]. The amounts of similar or alternating blocks is dependent upon the source of the 
alginate. G blocks are typically stiffer than M blocks due to intramolecular bonding between the 
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carboxyl and hydroxyl groups, therefore alternating these blocks increases the alginate solubility. 
A common crosslinking technique for alginate, called ionic crosslinking, involves using divalent 
cations (Ca2+ or Ba2+) to form bonds between carboxylic groups of neighboring G units.  
  Alginate stiffness changes with respect to composition following the trends: MG < MM < 
GG, while elasticity increases with GG < MM < MG. Therefore, alginate properties can be tuned 
by changing the M:G ratio, crosslinking method, and molecular weight [37]. While alginate is a 
natural polymer, it is foreign to mammalian cells and cannot be broken down by enzymes in vivo. 
In the case of ionically crosslinked alginate, degradation can occur by the release of crosslinking 
divalent ions into the surrounding medium for monovalent ions. As calcium ions are released, 
carboxyl anion repulsion further accelerates the swelling and erosion of the alginate chains [74]. 
Therefore, in vivo control of alginate degradation is poor. Additionally, mammalian cells do not 
naturally adhere to alginate and this material is relatively biologically inert. In order to improve 
cell adhesion, ECM proteins and peptides (such as collagen and RGD peptides) can be physically 
or chemically attached to alginate [28, 29]. 
Figure 6.Various natural polymers used for tissue engineering applications [8]. 
 
  Both chitosan and alginate are polymers that readily absorb excess fluid from their 
environment. Therefore, scaffolds made of either material can be more prone to degradation within 
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the physiological environment through bulk erosion. Forming PECs of chitosan and alginate 
allows for superior mechanical properties due to a lower degree of swelling. While chitosan was 
effectively degraded by lysozymes, the effect of these enzymes on the degradation of CA 
complexes was negligible due to strong interactions between the chitosan and alginate polymeric 
chains for almost 2.5 hours [77]. The stability of chitosan alginate PECs are influenced by charge 
ratio, molecular weight, ionic strength, pH, and mixing order [78]. Since polymer ratios can change 
the rate of biodegradation, chitosan alginate polymer blends have high potential for tissue 
engineering applications.   
Chitosan-Alginate Materials  
Polysaccharide biomaterials are of high relevance to the tissue engineering field since they 
are naturally derived and have a chemical structure that closely mimics that of glycosaminoglycans 
in native ECM. When cationic chitosan and anionic alginate are blended together in solution, they 
can form PECs due to electrostatic interactions. Chitosan-Alginate (CA) PEC formation is 
dependent on solution pH, polymer molecular weight, and alginate to chitosan ratio. While alginate 
is naturally non-adhesive to mammalian cells, CA materials exhibit better cell adhesion due to the 
ability of positively charged chitosan to adsorb serum proteins. Therefore, CA materials combine 
the advantages of its independent polymer components while reducing the drawbacks.  
CA materials can be processed to induce a phase separation that gives a porous 
microstructure to ensure cell attachment, tissue growth, and allow the flow of nutrients. This can 
be accomplished by freeze casting and freeze drying CA solutions. Scaffold porosity is dependent 
on many processing parameters, including freezing temperature, molecular weight of polymer, and 
polymer solution concentrations. Solution viscosity, which is dependent on concentration, has 
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been found to be the main parameter regulating pore structure and scaffold mechanical properties 
[79]. These parameters influence the shape and size of ice crystals that form scaffold pores after 
freeze drying. CA scaffolds have been previously fabricated to yield pore sizes from 100 to 300 
µm [1]. Additionally, CA scaffolds have been demonstrated to have superior mechanical properties 
than chitosan scaffolds due to strong ionic interactions between chitosan and alginate to form 
PECs.   
CA biomaterials investigated for tissue engineering applications with in vitro studies have 
been shown to promote cell adhesion and proliferation for cartilage, bone, and embryonic stem 
cell (ESC) cultures [79]. CA scaffolds demonstrated for bone tissue engineering with osteoblasts 
showed that cells attached to the scaffold, proliferated, and deposited calcified matrix. Also, 
calcium deposits on CA scaffolds were observed starting the fourth week after implantation [1]. 
CA scaffolds were also investigated for cartilage tissue engineering with HTB-94 cells, where cell 
proliferation was found to be faster in CA scaffolds than in pure chitosan scaffolds. Additionally, 
HTB-94 cells remained spherical in the CA scaffolds while showing an elongated morphology in 
the chitosan scaffolds [80]. CA scaffolds have also been investigated for culturing human 
embryonic stem cells (hESCS) and were demonstrated to support cell renewal without conditioned 
medium or feeder cell support [81].  
In addition to in vitro cell culture studies, CA scaffolds have been demonstrated to support 
functional bone tissue engineering in vivo with a critical size calvarial defect model. CA scaffolds 
were found to support undifferentiated MSCs in culture for 14 days in vitro with a spherical 
morphology. In vivo tests showed that the best defect closure was obtained for CA scaffolds with 
bone morphogenetic protein-2 (BMP-2) treatment [2].  
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Previous studies with CA scaffolds have demonstrated support of stem cell self-renewal 
while maintaining stem cells undifferentiated but only one CA scaffold composition (4 wt% CA) 
was investigated. By varying the CA scaffold concentration (2-6 wt% CA), we can evaluate if 
substrate stiffness guides BMSC differentiation into either adipogenic or osteogenic lineages. 
Therefore, this study will examine cell-material interactions in CA scaffolds and determine if 
mechanotransductive signaling from varying substrate stiffness can overcome BMSC stemness to 
support differentiation.   
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CHAPTER 3: METHODOLOGY  
Materials 
Chitosan (practical grade, >75% deacetylated, MW=190,000 - 375,000 Da), alginate (from 
brown algae), dexamethasone (DEX), isobutylmethylxanthine (IBMX), indomethacin (IM), -
glycerolphosphate (BGP), L-ascorbic acid 2-phosphate (LAA) were purchased from Sigma-
Aldrich (St. Louis, MO). Alpha minimum essential medium (-MEM), penicillin/streptomycin 
(P/S), L-glutamine (L-glut), Dulbecco’s phosphate buffered saline (D-PBS), trypsin-EDTA 
(0.25%), Alamar Blue solution, CellTracker chloromethyl-benzamidodialkylcarbocyanine (CM-
DiI) and Hoescht 33342 stains were purchased from Fisher Scientific (Waltham, MA). Fetal 
bovine serum (FBS) was purchased from Atlanta Biologicals (Atlanta, GA). Accumax was 
purchased from Innovative Cell Technologies (San Diego, CA). BMSCs from seven donors were 
purchased from RoosterBio (Frederick, MD). Additional information regarding BMSC donor 
gender and age can be found in Table 1.  
Table 1. BMSC donor information. 
Donor Sex Age 
12 M 33 
16 F 29 
37 M 43 
49 M 23 
55 M 22 
70 F 20 





CA scaffold synthesis  
2, 4, and 6 wt% CA scaffolds were prepared according to previously published methods 
[1, 2]. The chitosan and alginate solutions were prepared separately and equal amounts of chitosan 
and alginate were used to prepare the CA solutions. To synthesize a 4 wt% CA scaffold, 4 wt% 
chitosan and 4 wt% alginate solutions were prepared. A 4 wt% chitosan solution was prepared in 
1 wt% acetic acid and a 4 wt% alginate solution was prepared in DI water. Both solutions were 
prepared by dissolving the raw material powders in their respective solvents and mixing three 
times with a Thinky mixer (Thinky Corporation, Laguna Hills, CA) at 2000 rpm for several 
minutes. Excess heat in the mixer was dissipated between samples to keep mixing temperatures 
consistent in all solutions. Both solutions were aged overnight and mixed several times in a Thinky 
mixer. The 4 wt% chitosan solution with higher viscosity was added to the 4 wt% alginate solution 
with lower viscosity and the combined 4 wt% CA solution was mixed several times with a Thinky 
mixer at 2000 rpm. This step helps the formation of CA PECs. After mixing the solutions, the 4 
wt% CA solution was casted in 12-well plates and its pH was measured. CA samples were 
refrigerated at 4°C for 1 hour, frozen at -20 °C overnight, and lyophilized for 2 days. CA scaffolds 
were then sectioned at 2 mm thickness, crosslinked in 0.2 M CaCl2 for 15 minutes under vacuum, 
and washed three times with DI water. Sterilization was performed by soaking scaffolds in 70% 
ethanol solution for 30 minutes under vacuum, washing three times with D-PBS, and washing 
overnight with D-PBS in the shaker plate. The CA method was adapted to produce different 
scaffold properties by varying the polymer and acetic acid concentrations to yield 2, 4, and 6 wt% 






Table 2. 2, 4, and 6 wt% Alginate concentrations in DI water. 
Wt% Alginate (g) DI water (g) 
2 2.084 100 
4 4.167 100 
6 6.25 100 
 
Table 3. 2, 4, and 6 wt% Chitosan concentrations in acetic acid solutions. 
Wt% Chitosan (g) Acetic acid (g) DI water (g) 
2 2.084 0.5 99.5 
4 4.167 1.0 99.0 
6 6.25 1.5 98.5 
 
Scanning Electron Microscopy 
CA scaffold microstructure was analyzed with scanning electron microscopy (SEM). 
Samples were sputter coated with palladium-gold (Pd-Au) before being imaged with a JSM 6480 
(JEOL, Tokyo, Japan). Average pore sizes were determined by drawing five equally spaced line 
segments on the SEM micrographs at 50× magnification, counting the number of pores intersecting 
each line, and finding the ratio of intercepts to line length. This method was adapted from the 




The stiffness of the scaffolds were assessed in both wet and dry conditions at room 
temperature using the AGS-X mechanical tester (Shimadzu, Japan). The CA scaffolds were cut 
into 10 mm x 10 mm x 10 mm cubes and compressed at a rate of 0.4 mm/min using a 500 N load 
cell until reaching 40% of the initial height. Scaffolds were crosslinked with 0.2 M CaCl2, washed 
with D-PBS, and stored in D-PBS prior to mechanical compression testing for wet conditions. 
Young’s moduli were calculated from the slopes of the linear regions of the stress–strain curves. 
Fourier Transform Infrared Spectroscopy 
 PEC formation was assessed in the CA scaffold array with Fourier Transform Infrared 
(FTIR) Spectroscopy. Freeze dried scaffolds were ground with potassium bromide into a fine 
powder. The mixed powder was compressed to a transparent pellet of 0.8-1 mm thickness with 
the Quick Press KBr Pellet Kit (International Crystal Lab, Garfield, NJ). Scaffolds were analyzed 
with FTIR (Nexus 870, Thermo Scientific, Waltham, MA) with 300 scans at 8 cm-1 resolution. 
Cell culture  
BMSCs were expanded for six days in T-150 flasks (Corning, Waltham, MA). Cultures 
were maintained in fully supplemented -MEM with 16.5% FBS, 1% P/S, and 1% L-glut at 37 °C 
and 5% CO2 in a fully humidified incubator. BMSCs were detached with 0.25% Trypsin-EDTA. 
Prior to seeding, cell pellets were resuspended in D-PBS at 1×106 cell/mL. Then, cell solutions 
were stained with CellTracker CM-DiI stain (5 L/mL), incubated at 37 °C for 5 minutes, 4 °C for 
15 minutes, and washed three times with D-PBS. Afterwards, cell solutions were stained with 
Hoescht 33342 stain (1 L/mL), incubated at room temperature for 20 minutes, and washed three 
times with D-PBS. Cells were resuspended in media at 2×106 cell/mL concentration and seeded 
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dropwise onto damp CA scaffolds in 12-well plates at 200,000 cells per scaffold with 100 L of 
cell suspension. Scaffolds were incubated for 2 hours after cell seeding before 1.5 mL of cell media 
were added to the wells. For 2D samples, 500 µL of cell solution (100,000 cells) and 1 mL of cell 
media were added to the 12-well plate wells. Media was replaced at least every 2 days. The cultures 
were allowed to proliferate for 14 days, then the cultures were switched to adipogenic or osteogenic 
media and cultured for an additional 28 days to induce differentiation. Adipogenic media contained 
0.5 M DEX, 0.5 M IBMX, and 50 M IM in fully supplemented -MEM. Osteogenic media 
contained 10 nM DEX, 20 mM BGP, and 50 M LAA in fully supplemented -MEM. 
Cell proliferation analysis  
The Alamar Blue assay was used to assess cell proliferation in CA scaffolds and 2D wells 
at 2, 7, and 14 day timepoints following the manufacturer’s protocols. 1.5 mL of Alamar Blue 
solution (10 v/v% in media) was added to each sample well and incubated for 2.5 hours. 
Afterwards, the Alamar Blue solutions were transferred to a black-bottom 96-well plate and was 
read with fluorescence at 560 nm excitation, 590 nm emission with a Cytation5 imaging multi-
mode reader (Biotek, Winooski, VT). Samples were washed once with D-PBS and 1.5 mL of cell 
culture medium was added. Cell numbers were calculated from standard curves with known cell 
numbers for each cell donor.  
Cell imaging 
Live cell fluorescence imaging was performed to observe cell morphology and nuclei with 
CM-DiI and Hoescht 33342 stains at the 3, 7, and 14 day time points. Samples were imaged with 
the Cytation5 cell imaging multi-mode reader (Biotek, Winooski, VT) at 4× and 20× 
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magnifications with DAPI and RFP filters. Brightfield images were also obtained for all samples 
at both magnifications. 
Alizarin Red and Oil Red O staining  
Scaffolds and 2D samples were fixed with 3.7% formaldehyde solution for 1 hour and 
washed three times with D-PBS prior to staining. Samples treated with adipogenic differentiation 
media were immersed with 60% isopropanol for 10 minutes, stained with Oil Red O staining 
solution for 15 minutes, and washed three times with D-PBS. Samples treated with osteogenic 
differentiation media were processed to prepare slides for histology analysis using the Leica ASP 
300S tissue processor, Leica EG1150 C tissue embedder, and Leica RM 2235 microtome (Wetzlar, 
Germany). Histology samples were cut into 16 µm sections, mounted on slides, dewaxed, 
rehydrated, stained with Alizarin Red staining solution for 10 minutes, and washed three times 




CHAPTER 4: RESULTS AND DISCUSSION 
Scanning Electron Microscopy 
 Scaffolds of 2, 4, and 6 wt% CA concentrations were produced successfully and were 
stable in aqueous conditions after crosslinking. SEM images of all CA scaffold compositions (2, 
4, 6 wt%) were obtained at two different magnifications (50, 200) in order to better assess the 
pore structure changes resulting from variations in composition. CA scaffolds yielded an 
interconnected porous structure as a result of the sublimation of ice from CA solutions during 
lyophilization. Higher CA scaffold concentrations (4, 6 wt%) have smaller pore structures than 
lower CA scaffold concentrations (2 wt%), as can be observed in Figure 7.   
  
 





Porosity variations among the CA scaffold array compositions were also quantitatively 
assessed by calculating the average pore sizes for all CA scaffold compositions. Our approach was 
adapted from the ASTM E112-13 standard method for determining average grain sizes [82]. The 
average pore size values for 2, 4, and 6 wt% CA scaffolds can be found in Table 4. As expected, 
average pore sizes decrease with increasing CA scaffold concentrations. This occurs as increasing 
CA concentrations with higher polymer densities reduce the size of ice crystals formed, thereby 
giving an overall smaller microporous structure.  
 
Table 4. CA scaffold average pore sizes. 
Scaffolds  Average Pore Size (µm) Standard Deviation 
2% CA 233.3 23.7 
4% CA 208.2 37.9 




The elastic modulus of all CA scaffold compositions (2, 4, 6 wt%) was determined with 
compression mechanical testing (Figure 8). Besides measuring the elastic modulus of the CA 
scaffolds after lyophilization (dry condition), the elastic modulus of CA scaffolds was also tested 
under wet conditions. Samples prepared for the wet condition were crosslinked, sterilized, and 
washed overnight prior to compression testing. The elastic modulus of CA scaffolds in the wet 
condition was relevant since it better resembled the mechanical properties BMSCs are exposed 





Figure 8. CA scaffold compression mechanical testing under dry (A) and wet (B) conditions. 
 
 The mechanical properties of CA scaffolds in dry conditions were one to two orders of 
magnitudes higher than CA scaffolds in wet conditions. This decrease in Young’s modulus has 
also been observed in wet conditions compared to dry conditions by other research groups in a 
variety of polymer substrates [83]. This type of behavior is mainly due to the plasticizing effect of 
water in the CA scaffolds, which allows CA polymer chain fibers a greater freedom of motion. 
Due to higher porosity size at the lower CA scaffold concentrations, this plasticizing effect yields 
a lower elastic modulus for 2 wt% CA scaffolds than 4 and 6 wt% CA scaffolds.  
 Measuring the differences in CA scaffold stiffness under wet conditions (that mimic in 
vitro conditions) is key to understanding BMSC behavior, since BMSCs grow in the wet 
environment during cell culture. Moreover, it has been demonstrated that BMSCs commit to 
specific lineages with high sensitivity to matrix stiffness [75]. Substrate elasticity also affects other 
important cellular processes such as cell adhesion, growth, proliferation, and differentiation [84].  
CA scaffold elasticity values in the dry condition (0.22–5.34 kPa) best match the elastic 
modulus for brain tissue (0.1–1 kPa) with the 2 wt% CA scaffold stiffness (0.22 kPa). On the other 
hand, 4 and 6 wt% CA scaffolds in the dry condition (3.14 and 5.34 kPa) have stiffnesses values 
between the upper limit for brain and lower limit for muscle tissue (1–8 kPa). CA scaffold elasticity 
values in the wet condition (21.1–47.3 Pa) are lower than typical brain tissue stiffness 
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measurements. While previous studies have demonstrated 2D materials with similar stiffnesses to 
native tissue for BMSC differentiation into multiple lineages, the effects of 3D porous 
microenvironment stiffness variations on BMSC cell fate have not been established. Therefore, 
this study will help elucidate the relationship of CA scaffolds stiffness and BMSC differentiation.  
Fourier Transform Infrared Spectroscopy 
FTIR was performed for all CA scaffold compositions and in chitosan and alginate only 
scaffolds in order to confirm PEC formation (Figure 9). The characteristic peak in alginate for the 
carboxylic acid group can be observed at 1600 cm-1. The characteristic peaks in chitosan for the 
amide group and primary amine N-H bending were observed at 1650 and 1590 cm-1 respectively. 
The CA scaffold PEC formation was demonstrated by the merging of the characteristic peaks for 
chitosan and alginate to form a broader peak at 1630 cm-1. The characteristic peak at 1630 cm-1 
was observed in the 2, 4, and 6 wt% CA scaffolds, indicating PEC formation at all concentrations.  
 




Preliminary Study: Evaluation of Proliferation for Multiple BMSC Donors 
 Prior to starting the BMSC differentiation study, a preliminary trial testing the proliferation 
of 7 BMSC donors within the 4 wt% CA scaffold composition was carried out by using the Alamar 
Blue proliferation assay. All BMSC donors increased in cell number with increasing timepoints 
and BMSC donor 81 reached the highest cell number in the 4 wt% CA scaffold, as can be observed 
in Figure 10. 
 
Figure 10. BMSC Multiple Donor proliferation study in 4 wt% CA scaffolds. 
 
Additionally, all BMSC donors formed cell spheroids in the 4 wt% CA scaffolds as can be 
observed in Figure 11. Spheroid formation could be attributed to the fact that CA scaffolds are 
polysaccharide-based and lack matrix proteins to facilitate cell adhesion and cell spreading. 









Figure 11. BMSC donors cluster into cell spheroids in 4 wt% CA scaffolds at day 7 of proliferation. 
 
Spheroid size also varied with time for all CA scaffold compositions, with the greatest size 
of spheroids being observed at day 3 and decreasing afterwards, as can be observed in Figure 12. 
It is possible that at later timepoints, BMSCs begin to migrate within the scaffolds, thereby 




Figure 12. BMSC donor 12 in 4 wt% CA scaffolds at days 1, 3, and 7. Cell nuclei were observed with the 
Hoescht live fluorescent stain. 
 
 This preliminary study helped us evaluate the proliferation of the BMSC donors and also 
their cell morphology response to 2, 4, and 6 wt% CA scaffolds. For the rest of this thesis, three 
BMSC donors were chosen based on their proliferation capacity and CA scaffolds response. While 
donors 16, 70, and 81 showed the greatest proliferation, cell morphology response to the CA 
scaffolds was not consistent for donors 16 and 70. Donors 12 and 37 were the next two BMSC 
donors with highest proliferation capacity. Additionally, they showed a similar and consistent 
morphology response to the CA scaffolds as donor 81, with BMSC clustering of comparable size. 
Therefore, donors 12, 37, and 81 were chosen for this study due to their proliferation capacity and 
similar cell morphology response to the CA scaffolds.  
 
Table 5. Three selected BMSC donors for differentiation study. 
Donor  Sex Age 
12 M 33 
81 M 25 
37 M 43 
 
Cell proliferation 
In order to assess the proliferation of BMSCs in this study, we performed the Alamar Blue 
assay in all CA scaffold compositions and 2D substrates at days 2, 7, and 14 of proliferation. Cell 
numbers are highest in 2D samples than in any scaffold composition at all timepoints. This was 
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expected since tissue culture plates are treated to promote cell adhesion and proliferation, while 
CA scaffolds lack adhesion proteins and therefore can lower BMSC proliferation rates.  
As can be observed in Figure 13, the main trend among both scaffolds and 2D samples is 
an increase in cell number, especially apparent at the 14 day timepoint. Among the different 
scaffold groups, the 2% CA scaffold shows the greatest increase in cell numbers reaching close to 
400,000 cells at the fourteen day timepoint. Additionally, donor 81 yields the greatest cell numbers 
among all BMSC donors after the day 3 timepoint. 
The Alamar Blue proliferation assay gave us important insights regarding differences in 
proliferation within BMSC donors and materials. It is noticeable that there are differences in 
proliferation capacity between BMSC donors since all samples were seeded with the same cell 
concentration but yielded different cell numbers at later timepoints. Even when donors 12 and 81 
yielded similar cell numbers at the day 3 timepoint in 2% CA and 6% CA samples, this trend was 
not maintained. Donor 81 yielded much higher cell numbers at later timepoints. Therefore, the 
Alamar Blue data indicates that there are inherent differences in the proliferation capacity among 
BMSC donors and confirms our results from the preliminary proliferation study of multiple BMSC 
donors. Additionally, BMSCs in the 2% CA scaffold reached higher cell numbers than in the 4% 
CA and 6% CA scaffold compositions. This indicates that there may be a difference in BMSC 
proliferation capacity with different scaffold stiffnesses.  
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Figure 13. Alamar Blue data for BMSCs in 2, 4, 6 wt% CA and 2D substrates at days 2, 7, and 14. 
 
Cell Imaging 
Cell imaging was performed with the Hoescht 33342 and DiI live fluorescent stains. The 
Hoescht dye identified the cell nuclei, while the DiI dye helped visualize the cell morphology. At 
day 3 of proliferation, all BMSC donors clustered into spheroids in the 2, 4, and 6 wt% CA 
scaffolds while remaining elongated in 2D substrates, as can be observed in Figure 14 which shows 
overlaid images of both live fluorescent dyes. Bigger spheroids were observed at the higher CA 
scaffold concentrations (4, 6 wt% CA), while smaller spheroids were seen at the lower CA scaffold 
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concentrations (2 wt% CA). The BMSC clustering response within the CA scaffolds may be due 
to its polysaccharide based chemistry and absence of adhesion proteins.  
 
 
Figure 14. BMSC donors 12, 37, and 81 in 2, 4, 6 wt% CA scaffolds and 2D substrates at day 3 of 
proliferation were stained Hoechst and DiI live fluorescent dyes. 
  
Similar trends regarding BMSC spheroid size and CA scaffold composition were observed 
at the 7 and 14 day timepoint as can be observed in Figures 15 and 16, with higher spheroid size 
corresponding to the stiffer substrates and vice versa. Additionally, cells in 2D substrates remained 
elongated at all timepoints and increased in confluency. It was also observed that the DiI staining 
intensity decreased with increasing timepoints, specially in BMSCs seeded on 2D substrates. This 
occurs since the DiI stain binds to the cell membrane and therefore decreases in concentration as 




Figure 15. BMSC donors 12, 37, and 81 in 2, 4, 6 wt% CA scaffolds and 2D substrates at day 7 of 





Figure 16. BMSC donors 12, 37, and 81 in 2, 4, 6 wt% CA scaffolds and 2D substrates at day 14 of 
proliferation were stained Hoechst and DiI live fluorescent dyes. 
 
Spheroid size also varied at different timepoints, as can be seen in Figure 17 for BMSC 
donor 81 in 2, 4, and 6 wt% CA scaffold at days 3, 7, and 14 of proliferation. The greatest spheroid 
size was observed at the day 3 timepoint and decreased afterward. These observations were 
consistent with the preliminary results from the multiple donor BMSC study in Figure 10. We 
believe decreasing spheroid size could be due to increased cell migration out of the spheroids into 




Figure 17. BMSC Donor 81 in 2, 4, 6 wt% CA scaffolds at 3, 7, 14 day timepoints of proliferation. 
 
Oil Red O and Alizarin Red Staining 
  Oil Red O 
 BMSCs cultured on 2D substrates with adipogenic differentiation medium were stained 
with Oil Red O dye after 14 and 28 days of differentiation. As can be observed in Figure 18 and 
19, the Oil Red O staining solution stains lipid droplets red indicating adipogenic differentiation 
in BMSCs. Therefore, adipogenic differentiation was achieved in this study among all BMSC 
donors in the 2D substrates at 14 and 28 days of differentiation.  
While adipogenic differentiation occurred among all BMSC donors, the extent of 
differentiation varied. As can be observed in the lower magnification images of Figures 18 and 19, 
donor 12 had less positive Oil Red O staining than donor 37 and, similarly, donor 37 had less 
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positive staining than donor 81. Additionally, the size of the BMSC fat droplets was higher for 
donor 81 than for donors 12 or 37. Therefore it is not only important to study a single BMSC donor 
response to a specific substrate or scaffold, but also to look at multiple donor responses since they 
can give varied results even as control (2D) groups. 
 
Figure 18. Oil Red O staining on BMSC donors in 2D substrates at 14 days of adipogenic differentiation. 
 
Besides donor variation, differences in the extent of differentiation were also observed at 
different timepoints. Lipid droplets deposited by BMSCs undergoing adipogenic differentiation 
are larger in size at the day 28 differentiation timepoint, as can be observed in Figure 19. Greater 





Figure 19. Oil Red O staining on BMSC donors in 2D substrates at 28 days of adipogenic differentiation. 
 
BMSCs cultured in 2, 4, and 6 wt% CA scaffolds under adipogenic differentiation medium 
were stained with Oil Red O dye after 14 and 28 days of differentiation. Higher magnification 
images from the 14 and 28 days of differentiation staining can be seen in Figures 20 and 21 
respectively, where lipid droplets are stained red in all CA compositions and BMSC donors. Yet, 
there is a clear distinction in the extent of adipogenic differentiation between materials and donors. 
Lipid droplets are larger in size in 4 wt% CA and 6 wt% CA materials, while smaller in 2 wt% CA 
materials. Additionally, donors 37 and 81 showed the largest size of lipid formation which 
indicates a higher extent of adipogenic differentiation. Overview images of the CA scaffolds for 
both timepoints are shown in Figures 22 and 23. These images demonstrate the sparse positive 
























Alizarin Red  
BMSCs cultured on 2D substrates with osteogenic differentiation medium were stained 
with Alizarin Red dye after 14 and 28 days of differentiation. As can be observed in Figure 24 and 
25, the Alizarin Red solution stains calcium deposits in the matrix indicating osteogenic 
differentiation in BMSCs. Therefore, osteogenic differentiation was achieved in this study among 
all BMSC donors in the 2D substrates at 14 and 28 days of differentiation.  
While osteogenic differentiation occurred among all BMSC donors, the extent of 
differentiation varied. As can be observed in the overview images of Figures 25, donor 37 showed 
a greater extent of osteogenic differentiation than donors 12 and 81. Additionally, the extent of 
osteogenic differentiation increased from day 14 to day 28.  
 
 





Figure 25. Alizarin Red staining on BMSC donors in 2D at 28 days of osteogenic differentiation. 
 
BMSC samples cultured in 2, 4, and 6 wt% CA scaffolds under osteogenic differentiation 
medium were stained with Alizarin Red dye after 14 and 28 days of differentiation. In Figure 26, 
we can observe overview images for 2, 4, and 6 wt% CA samples at 14 days of osteogenic 
differentiation media treatment. The positive red stain indicates osteogenic differentiation among 
all donors and CA scaffold samples. Moreover, the darker spots indicate bone nodule formation 
due to matrix mineralization. In day 14 samples, matrix mineralization was higher for samples in 




Figure 26. BMSC donors in 2, 4, 6 wt% CA scaffolds were stained with Alizarin Red after 14 
days of osteogenic differentiation. 
 
 BMSC samples at 28 days of osteogenic differentiation were also processed for histology 
and stained with Alizarin Red solution to analyze the extent of mineralization as can be observed 
in Figure 27. Similarly to the day 14 differentiation results, all scaffold samples and BMSC donors 
stained positively for osteogenic differentiation with Alizarin Red. 4 wt% CA and 6 wt% CA 
samples exhibited greater matrix mineralization than 2 wt% CA samples indicated by bone nodule 
formation. These results support our initial hypothesis, where stiffer substrates support greater 
BMSC osteogenic differentiation and matrix mineralization. Higher magnification images for both 
days 14 and 28 of osteogenic differentiation can be found in Figures 28 and 29, which more clearly 
show nodule formation from calcium deposits in the scaffold. Greater mineralization at higher CA 
scaffold stiffnesses supports that BMSC osteogenic differentiation is influenced by substrate 








Figure 28. High magnification images of BMSC donors in 2, 4, 6 wt% CA scaffolds were stained with 





Figure 29. High magnification images of BMSC donors in 2, 4, 6 wt% CA scaffolds were stained with 
Alizarin Red after 28 days of osteogenic differentiation  
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 CHAPTER 5: CONCLUSIONS  
This thesis examined the effects of CA scaffold stiffness variation on BMSC adipogenic 
and osteogenic differentiation. An array of CA scaffolds (2, 4, 6 wt% CA) was produced by 
varying the polymer concentrations. CA scaffolds were fabricated by freeze casting and 
lyophilization to yield an interconnected porous structure. The CA porous scaffold array had 
different mechanical properties but the same chemical composition.  
In order to characterize the CA scaffold properties, SEM, compression mechanical testing, 
and FTIR were performed. SEM images and average pore size calculations demonstrated 
decreasing pore sizes at higher CA scaffold concentrations. Compression mechanical testing 
yielded higher elastic moduli values for higher CA scaffold concentrations in both dry and wet 
conditions, with wet conditions giving values two orders of magnitude lower than dry conditions. 
FTIR data demonstrated the formation of PECs at all CA scaffold compositions.  
Three BMSC donors were seeded on the CA scaffold array to examine the cell response to 
different scaffold stiffnesses and BMSC donor variation. The cell culture study included a 14 day 
proliferation phase, followed by 28 days of differentiation under adipogenic or osteogenic 
differentiation media. The Alamar Blue proliferation assay showed an increase in cell number at 
the 14 day timepoint for all CA scaffold compositions and BMSC donors. BMSC donors 37 and 
81 showed higher cell numbers than donor 12 at most timepoints in the alamar blue assay. BMSCs 
formed spheroids in all CA scaffold compositions, with higher stiffnesses (4, 6 wt% CA) 
promoting larger spheroid formation than lower stiffnesses (2 wt% CA). Spheroid size for all CA 
scaffold compositions and BMSC donors decreased after day 3 of proliferation possibly due to cell 
migration in the scaffold.  
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After 28 days of adipogenic differentiation, BMSCs in CA scaffolds and 2D samples were 
stained with Oil Red O dye to target lipid droplets indicating adipogenic commitment. In 2D 
samples, the largest positive Oil Red O staining was observed for donor 81, followed by donors 
37 and 12 respectively. In the CA scaffold array, the greatest Oil Red staining was observed for 
donors 37 and 81 in the 4 and 6 wt% CA scaffolds.  
While positive Oil Red O staining was observed for all scaffold compositions, more robust 
differentiation was expected at the lower CA scaffold concentrations (2 wt% CA). Therefore this 
study disproved our hypothesis for the adipogenic differentiation group. The polysaccharide 
composition of the CA scaffolds likely contributed to the spheroid formation and influenced the 
extent of differentiation. It can be noted that the largest adipogenic differentiation was observed in 
scaffolds that yielded the largest cell clusters (4, 6 wt%).  
The extent of osteogenic differentiation was also assessed for BMSCs in CA scaffolds and 
2D samples with Alizarin Red dye to target calcium deposits indicating osteogenic differentiation. 
In 2D samples, the largest Alizarin Red staining was observed for donor 37. Additionally, the 
extent of osteogenic differentiation increased from day 14 to day 28 among all BMSC donors. In 
the CA scaffolds, all compositions stained positively for osteogenic differentiation at both day 14 
and day 28 of differentiation. Stiffer substrates (4, 6 wt% CA) exhibited greater mineralization 
than softer substrates (2 wt% CA) indicated by matrix darkening, also called bone nodule 
formation, surrounded by positive Alizarin Red staining. While all CA compositions and BMSC 
donors supported osteogenic differentiation, scaffolds with higher stiffnesses showed a greater 
extent of osteogenic differentiation indicated by matrix mineralization. Therefore, samples treated 
for osteogenic differentiation supported our initial hypothesis that stiffer scaffold substrates would 
further guide BMSCs towards osteogenic lineage differentiation. 
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For both adipogenic and osteogenic differentiation, the greatest extent of differentiation 
occurred in the 4 and 6 wt% CA scaffolds relative to the 2 wt% CA scaffolds. These scaffold 
compositions also formed the largest cell spheroids, which studies have associated with stemness 
markers [85]. It is possible that 4 and 6 wt% CA scaffolds helped maintain BMSC stemness during 
the proliferation phase indicated by the larger cell clusters, which could contribute to a greater 
extent of differentiation. Further optimization of the CA scaffolds will be needed in order to 
examine the effects of scaffold stiffness independently of the effects of polysaccharide chemistry 
and spheroid formation on BMSC differentiation. Protein based coatings could be adsorbed onto 
the CA scaffolds to enhance BMSC adhesion, proliferation, and differentiation, while changing 
the cell morphology from a spherical to an elongated shape. Additionally, increasing scaffold cell 




APPENDIX A: BMSC DONOR 81 STANDARD CURVE FOR ALAMAR 





(A) List of intensity readings from the Alamar Blue assay at different cell numbers from 0 to 1.5 
million. Blank readings were subtracted from these intensity values. 
 







APPENDIX B: OVERVIEW IMAGES OF BMSCS IN CA SCAFFOLD 






























APPENDIX C: ALIZARIN RED CONTROL STAINING OF 2, 4, 6 WT% 







Control staining of Alizarin Red solution in 2, 4, 6 wt% CA scaffolds without BMSCs 
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